{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:00:12Z","timestamp":1790251212722,"version":"4.1.0"},"reference-count":40,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"three-year action plan for strengthening the construction of the public health system in Shanghai","award":["GWVI-11.2-YQ44"],"award-info":[{"award-number":["GWVI-11.2-YQ44"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a novel tick-borne bunyavirus, causing the hemorrhagic infectious disease of SFTS, with a case fatality rate up to 30% due to the absence of effective therapeutic interventions. Therefore, it is urgent to develop safe and effective therapeutic drugs to control this viral hemorrhagic fever. Methods: The activity of verteporfin (VP), screened from an FDA-approved drugs library, against SFTSV, was systematically evaluated in Huh7 cells in a wide range of concentrations. We performed time-of-addition experiments with VP, along with binding, endocytosis, and membrane fusion assays, to determine which part of the SFTSV life cycle VP has its effect on. The potential targets of VP were detected by a drug affinity responsive target stability (DARTS) assay. Results: VP exhibited a potent anti-SFTSV activity by blocking the initial viral binding to the target cells during viral entry via significantly inducing the degradation of the viral Gn protein. Conclusions: The VP-induced inhibition of SFTSV binding, the first step of viral invasion, suggested that VP might be an ideal and potent anti-SFTSV agent due to its prophylaxis and therapeutic effects on viral infection.<\/jats:p>","DOI":"10.3390\/pharmaceutics17040434","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T06:06:35Z","timestamp":1743141995000},"page":"434","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Verteporfin Inhibits Severe Fever with Thrombocytopenia Syndrome Virus Infection via Inducing the Degradation of the Viral Gn Protein"],"prefix":"10.3390","volume":"17","author":[{"given":"Bingan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Lin","sequence":"additional","affiliation":[{"name":"College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtian","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijing","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41422-019-0214-z","article-title":"Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality","volume":"29","author":"Li","year":"2019","journal-title":"Cell Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/15548627.2024.2393067","article-title":"Bunyavirus SFTSV nucleoprotein exploits TUFM-mediated mitophagy to impair antiviral innate immunity","volume":"21","author":"Zhang","year":"2025","journal-title":"Autophagy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1056\/NEJMoa1010095","article-title":"Fever with thrombocytopenia associated with a novel bunyavirus in China","volume":"364","author":"Yu","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e01684-19","DOI":"10.1128\/JVI.01684-19","article-title":"Severe Fever with Thrombocytopenia Syndrome Virus NSs Interacts with TRIM21 To Activate the p62-Keap1-Nrf2 Pathway","volume":"94","author":"Choi","year":"2020","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fang, X., Hu, J., Peng, Z., Dai, Q., Liu, W., Liang, S., Li, Z., Zhang, N., and Bao, C. (2021). Epidemiological and clinical characteristics of severe fever with thrombocytopenia syndrome bunyavirus human-to-human transmission. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009037"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41541-024-00993-y","article-title":"Adenovirus type 5-expressing Gn induces better protective immunity than Gc against SFTSV infection in mice","volume":"9","author":"Qian","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1038\/s44319-024-00310-7","article-title":"Severe fever with thrombocytopenia syndrome virus induces lactylation of m6A reader protein YTHDF1 to facilitate viral replication","volume":"25","author":"Liu","year":"2024","journal-title":"EMBO Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"eadg6856","DOI":"10.1126\/sciadv.adg6856","article-title":"CCR2 is a host entry receptor for severe fever with thrombocytopenia syndrome virus","volume":"9","author":"Zhang","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kim, E.H., and Park, S.J. (2023). Emerging Tick-Borne Dabie bandavirus: Virology, Epidemiology, and Prevention. Microorganisms, 11.","DOI":"10.3390\/microorganisms11092309"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/d41586-024-02513-3","article-title":"The pathogens that could spark the next pandemic","volume":"632","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00705-024-05968-x","article-title":"Characterization of antibodies targeting severe fever with thrombocytopenia syndrome virus glycoprotein Gc","volume":"169","author":"Sano","year":"2024","journal-title":"Arch. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Moming, A., Shi, S., Shen, S., Qiao, J., Yue, X., Wang, B., Ding, J., Hu, Z., Deng, F., and Zhang, Y. (2021). Fine mapping epitope on Glycoprotein-Gn from Severe Fever with Thrombocytopenia Syndrome Virus. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248005"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jeon, P., Yoo, B., Kim, Y., Lee, S.Y., Woo, H.M., Lim, H.Y., Lee, J.Y., Park, S., and Lee, H. (2024). Characterization of high-affinity antibodies against the surface Gc protein of Dabie bandavirus\/severe fever with thrombocytopenia syndrome virus. Biochem. Biophys. Rep., 39.","DOI":"10.1016\/j.bbrep.2024.101779"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2400163121","DOI":"10.1073\/pnas.2400163121","article-title":"Bispecific antibodies targeting two glycoproteins on SFTSV exhibit synergistic neutralization and protection in a mouse model","volume":"121","author":"Chang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E7564","DOI":"10.1073\/pnas.1705176114","article-title":"Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope","volume":"114","author":"Wu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e0181523","DOI":"10.1128\/jvi.01815-23","article-title":"Interaction between the SFTSV envelope glycoprotein Gn and STING inhibits the formation of the STING-TBK1 complex and suppresses the NF-\u03baB signaling pathway","volume":"98","author":"Jia","year":"2024","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1185\/030079907X167624","article-title":"Verteporfin photodynamic therapy and anti-angiogenic drugs: Potential for combination therapy in exudative age-related macular degeneration","volume":"23","author":"Kaiser","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Huang","year":"2012","journal-title":"Genes Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199475","DOI":"10.1016\/j.virusres.2024.199475","article-title":"Verteporfin is an effective inhibitor of HCMV replication","volume":"350","author":"Lim","year":"2024","journal-title":"Virus Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/157016208783885001","article-title":"Photopheresis in HIV-1 infected patients utilizing benzoporphyrin derivative (BPD) verteporfin and light","volume":"6","author":"Bernstein","year":"2008","journal-title":"Curr. HIV Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.scib.2020.12.005","article-title":"Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2","volume":"66","author":"Gu","year":"2021","journal-title":"Sci. Bull."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41586-020-2348-z","article-title":"Potential circadian effects on translational failure for neuroprotection","volume":"582","author":"Esposito","year":"2020","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-0716-0954-5_15","article-title":"Drug Affinity Responsive Target Stability (DARTS) Assay to Detect Interaction Between a Purified Protein and a Small Molecule","volume":"2213","author":"Huang","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Shen, S., Zhang, Y., Yin, Z., Zhu, Q., Zhang, J., Wang, T., Fang, Y., Wu, X., Bai, Y., and Dai, S. (2022). Antiviral activity and mechanism of the antifungal drug, anidulafungin, suggesting its potential to promote treatment of viral diseases. BMC Med., 20.","DOI":"10.1186\/s12916-022-02558-z"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12250-016-3858-6","article-title":"Entry of severe fever with thrombocytopenia syndrome virus","volume":"32","author":"Yuan","year":"2017","journal-title":"Virol. Sin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/22221751.2022.2049983","article-title":"Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo","volume":"11","author":"Qian","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ren, Y.S., Li, H.L., Piao, X.H., Yang, Z.Y., Wang, S.M., and Ge, Y.W. (2021). Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: Principles and application. Biochem. Pharmacol., 194.","DOI":"10.1016\/j.bcp.2021.114798"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/cid\/cit530","article-title":"Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome","volume":"57","author":"Liu","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Suemori, K., Saijo, M., Yamanaka, A., Himeji, D., Kawamura, M., Haku, T., Hidaka, M., Kamikokuryo, C., Kakihana, Y., and Azuma, T. (2021). A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009103"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00954-18","DOI":"10.1128\/JVI.00954-18","article-title":"Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library","volume":"92","author":"Wang","year":"2018","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"290ra89","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Plegge, T., Hofmann-Winkler, H., Spiegel, M., and P\u00f6hlmann, S. (2016). Evidence that Processing of the Severe Fever with Thrombocytopenia Syndrome Virus Gn\/Gc Polyprotein Is Critical for Viral Infectivity and Requires an Internal Gc Signal Peptide. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166013"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1128\/JVI.00110-16","article-title":"Characterization of Glycoprotein-Mediated Entry of Severe Fever with Thrombocytopenia Syndrome Virus","volume":"90","author":"Tani","year":"2016","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted Cancer Therapy: The Next Generation of Cancer Treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tips.2020.04.005","article-title":"Emerging New Concepts of Degrader Technologies","volume":"41","author":"Ding","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/bph.13096","article-title":"Ten things you should know about protein kinases: IUPHAR Review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8832","DOI":"10.1039\/D2CS00624C","article-title":"Emerging degrader technologies engaging lysosomal pathways","volume":"51","author":"Ding","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/v2040796","article-title":"Alphavirus Entry and Membrane Fusion","volume":"2","author":"Kielian","year":"2010","journal-title":"Viruses"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.virol.2022.02.001","article-title":"The interactions of flaviviruses with cellular receptors: Implications for virus entry","volume":"568","author":"Anwar","year":"2022","journal-title":"Virology"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/4\/434\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:04:12Z","timestamp":1760029452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/4\/434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["pharmaceutics17040434"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17040434","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}